ERBB2 and breast carcinoma: Silvestrini et al. (2017) demonstrated that priming with TLR agonist -CpG- and aPD-1 in a HER2+BC metastatic breast cancer model (NDL, immune-excluded TME, and low TMB) upregulates innate anti-tumor responses and alters infiltrated macrophage polarization after T-HIFU [85].